Your early phase study is Celerion’s core business.
Celerion, a leader in early clinical research, leverages its experience, expertise and specially equipped facilities to investigate early signals of efficacy for new treatments of metabolic-based diseases including diabetes, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH) and obesity. Our clients benefit from Celerion’s comprehensive knowledge of specialized metabolic testing methods and hands-on operational experience that supports early Proof-of-Concept in the development of diabetes, obesity, NAFLD/NASH and cardio-metabolic interventions.
We help you explore potential solutions for your drug development program. Whether your investigational target has a body weight reduction, anti-fibrosis or improved cardiovascular risk indication, Celerion delivers key pharmacodynamic endpoints to successfully support your early clinical studies. We have conducted hundreds of studies and thousands of procedures ensuring robust study designs are developed for optimal success. This experience ensures that we are able to anticipate potential issues and address them to deliver high-quality data within your study timeline.